Denis Becker, MD
Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1750359113
Payments from drug & device makers
Across 1,333 payments — averaging $344.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$194K
- Lilly USA, LLC$109K
- Merck$59K
- Sanofi-aventis U.S. LLC$23K
- Johnson & Johnson$20K
- Mannkind Corporation$19K
- plus $36K from 47 others
What the payments were for
- Consulting fees$9,9802%
- Speaking & faculty fees$371,72781%
- Travel & lodging$53,22112%
- Food & beverage$24,2105%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$92,428
- MOUNJARO$83,483
- RYBELSUS$77,916
- STEGLATRO$52,827
- INVOKANA$19,591
- AFREZZA$17,834
- SOLIQUA 100/33$13,718
- Tresiba$13,504
- TOUJEO$8,485
- BAQSIMI$8,200
- Synthroid$7,474
- Tirosint$4,625
- Xultophy 100/3.6$3,905
- Korlym$2,859
- TEPEZZA$2,037
- FARXIGA$1,984
- Tirosint-SOL$1,125
- EVENITY$860
- iLet Bionic Pancreas$418
- CeQur Simplicity$311
How this compares
$459,299 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $240,421 |
| JardianceEmpagliflozin | 122 | $115,238 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $111,516 |
| AfrezzaInsulin Regular, Human | 41 | $85,024 |
| RybelsusSemaglutide | 67 | $84,801 |
| TymlosAbaloparatide | 31 | $81,613 |
| ProliaDenosumab | 31 | $53,708 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $52,290 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $52,135 |
| MounjaroTirzepatide | 39 | $43,161 |
| FarxigaDapagliflozin Propanediol | 39 | $42,472 |
| OmnitropeSomatropin | 12 | $41,861 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $38,591 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $37,209 |
| TradjentaLinagliptin | 39 | $31,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $194,366 | $346,930263 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $400 | $159,439178 claims |
| Mannkind CorporationAfrezza | $19,036 | $85,02441 claims |
| Radius Health, Inc.Tymlos | $363 | $81,61331 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Trulicity, Humalog | $108,728 | $77,35083 claims |
| AmgenProlia | $4,363 | $53,70831 claims |
| AstraZenecaFarxiga | $2,319 | $42,47239 claims |
| AbbVieSynthroid | $16,188 | $31,105380 claims |
| MerckJanuvia | $58,536 | $26,29526 claims |
| Antares Pharma, Inc.Xyosted | $279 | $19,55629 claims |
| IBSA Pharma Inc.Tirosint | $3,355 | $10,79737 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $7,235718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Raleigh
- Corey BerlinRaleigh$742K
- Elizabeth HoltRaleigh$167K
- Julia Warren-UlanchRaleigh$31K
- Bhairavi SheshadriRaleigh$28K
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.